drugset / Trial / NCT05928455
The Immunogenicity and Safety Following a Heterologous Booster Dose of Recombinant SARS-CoV-2 Vaccine LYB001
Phase 0
Unknown
120 enrolled
Guangzhou Patronus Biotech Co., Ltd.
Affiliated Hospital of North Sichuan Medical College · collabYantai Patronus Biotech Co., Ltd. · collab
RandomizedParallel-groupOpen-labelPrevention
Summary
The goal of this clinical trial is to assess the immunogenicity and safety following a heterologous booster dose of recombinant SARS-CoV-2 vaccine (CHO cell) LYB001 in adults 18-59 years of age completed two- or three-dose inactivated COVID-19 vaccine. The main questions it aims to answer are: * whether LYB001 group is better on immunogenicity than the control group of inactivated vaccine? * whether LYB001 group has better performance on safety than the control group of inactivated vaccine, such as the lower adverse reaction rate?
Timeline
- Start
- 2022-05-14
- Primary completion
- 2022-10-10
- Completion
- 2023-06-30